FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030356048> ?p ?o ?g. }

• W2030356048 endingPage "97" @default.
• W2030356048 startingPage "97" @default.
• W2030356048 abstract "Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and 0% in PV, 60%, 20%, and 3% in ET, and 60%, 25%, and 7% in PMF. These mutations might be accompanied by other mutations that are less specific to myeloproliferative neoplasms but are prognostically relevant, such as additional sex combs-like 1 (ASXL1). Characteristic bone marrow morphology is required for World Health Organization-compliant diagnosis, especially in distinguishing ET from prefibrotic PMF and masked PV. Survival is the longest in ET, although still inferior to that of the age- and sex-matched control population; median survivals for patients younger than 60 years are approximately 33 years for ET, 24 for PV, and 15 for PMF. Major disease complications include thrombosis and leukemic or fibrotic transformation. In PV and ET, risk factors for survival include older age, leukocytosis, and thrombosis, whereas JAK2 mutation in ET is associated with increased risk of thrombosis. In PMF, type 1 or type 1-like CALR mutations are associated with superior and ASXL1 with inferior survival. Prevention of thrombosis in PV is secured by phlebotomy (hematocrit target <45%) and in both PV and ET by low-dose aspirin therapy; high-risk patients derive additional antithrombotic benefit from cytoreductive therapy with hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of choice. Although the JAK inhibitor ruxolitinib was recently approved for use in hydroxyurea-resistant PV, its role in routine clinical practice remains debatable. In myelofibrosis, stem cell transplant is the current treatment of choice for genetically or clinically high-risk disease; for all other patients requiring treatment, participation in clinical trials may be preferred because currently available drugs, including JAK inhibitors, are palliative and not shown to be disease modifying." @default.
• W2030356048 created "2016-06-24" @default.
• W2030356048 creator A5016216479 @default.
• W2030356048 creator A5024612499 @default.
• W2030356048 date "2015-04-01" @default.
• W2030356048 modified "2023-10-01" @default.
• W2030356048 title "Myeloproliferative Neoplasms" @default.
• W2030356048 cites W1550890813 @default.
• W2030356048 cites W1604100901 @default.
• W2030356048 cites W1605230984 @default.
• W2030356048 cites W166660488 @default.
• W2030356048 cites W1964863089 @default.
• W2030356048 cites W1970995807 @default.
• W2030356048 cites W1971237273 @default.
• W2030356048 cites W1972914723 @default.
• W2030356048 cites W1975135941 @default.
• W2030356048 cites W1979832242 @default.
• W2030356048 cites W1983262956 @default.
• W2030356048 cites W1983925960 @default.
• W2030356048 cites W1985994644 @default.
• W2030356048 cites W1988019098 @default.
• W2030356048 cites W1990444790 @default.
• W2030356048 cites W1995149934 @default.
• W2030356048 cites W1999025699 @default.
• W2030356048 cites W2012686883 @default.
• W2030356048 cites W2017299352 @default.
• W2030356048 cites W2018254868 @default.
• W2030356048 cites W2024359105 @default.
• W2030356048 cites W2025592929 @default.
• W2030356048 cites W2028803880 @default.
• W2030356048 cites W2030868349 @default.
• W2030356048 cites W2031978224 @default.
• W2030356048 cites W2036204941 @default.
• W2030356048 cites W2037516919 @default.
• W2030356048 cites W2041981155 @default.
• W2030356048 cites W2049145190 @default.
• W2030356048 cites W2049965335 @default.
• W2030356048 cites W2052451894 @default.
• W2030356048 cites W2058557527 @default.
• W2030356048 cites W2060707701 @default.
• W2030356048 cites W2063756127 @default.
• W2030356048 cites W2064418869 @default.
• W2030356048 cites W2064812526 @default.
• W2030356048 cites W2067829130 @default.
• W2030356048 cites W2067978068 @default.
• W2030356048 cites W2069651950 @default.
• W2030356048 cites W2072881492 @default.
• W2030356048 cites W2073726802 @default.
• W2030356048 cites W2085128863 @default.
• W2030356048 cites W2087172868 @default.
• W2030356048 cites W2087793617 @default.
• W2030356048 cites W2089993696 @default.
• W2030356048 cites W2094456737 @default.
• W2030356048 cites W2097692898 @default.
• W2030356048 cites W2100293053 @default.
• W2030356048 cites W2107139993 @default.
• W2030356048 cites W2113792044 @default.
• W2030356048 cites W2116878961 @default.
• W2030356048 cites W2118555215 @default.
• W2030356048 cites W2119941797 @default.
• W2030356048 cites W2123587611 @default.
• W2030356048 cites W2123633897 @default.
• W2030356048 cites W2126816979 @default.
• W2030356048 cites W2127790034 @default.
• W2030356048 cites W2134543618 @default.
• W2030356048 cites W2138709799 @default.
• W2030356048 cites W2146142395 @default.
• W2030356048 cites W2149858388 @default.
• W2030356048 cites W2157694607 @default.
• W2030356048 cites W2158156680 @default.
• W2030356048 cites W2162619595 @default.
• W2030356048 cites W2171735954 @default.
• W2030356048 cites W2213345967 @default.
• W2030356048 cites W2283150235 @default.
• W2030356048 cites W2320032845 @default.
• W2030356048 cites W240698351 @default.
• W2030356048 cites W46453237 @default.
• W2030356048 cites W803477619 @default.
• W2030356048 doi "https://doi.org/10.1001/jamaoncol.2015.89" @default.
• W2030356048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26182311" @default.
• W2030356048 hasPublicationYear "2015" @default.
• W2030356048 type Work @default.
• W2030356048 sameAs 2030356048 @default.
• W2030356048 citedByCount "247" @default.
• W2030356048 countsByYear W20303560482015 @default.
• W2030356048 countsByYear W20303560482016 @default.
• W2030356048 countsByYear W20303560482017 @default.
• W2030356048 countsByYear W20303560482018 @default.
• W2030356048 countsByYear W20303560482019 @default.
• W2030356048 countsByYear W20303560482020 @default.
• W2030356048 countsByYear W20303560482021 @default.
• W2030356048 countsByYear W20303560482022 @default.
• W2030356048 countsByYear W20303560482023 @default.
• W2030356048 crossrefType "journal-article" @default.
• W2030356048 hasAuthorship W2030356048A5016216479 @default.
• W2030356048 hasAuthorship W2030356048A5024612499 @default.
• W2030356048 hasConcept C71924100 @default.
• W2030356048 hasConceptScore W2030356048C71924100 @default.

• next